Go offline with the Player FM app!
NSAIDs, mAbs, & More: An OA Conversation with Dr. Innes
Manage episode 519211772 series 2641903
NSAIDs have long been the cornerstone of pharmaceutical pain relief for dogs with OA. But with the arrival of an OA monoclonal antibody therapy, is it time to rethink our approach? In this episode of Clinician’s Brief Partner Podcast, Dr. Beth invites renowned orthopedic expert Dr. John Innes to discuss how he approaches OA management, drawing from >4 years of experience with bedinvetmab in the United Kingdom. They also dive into a head-to-head study comparing bedinvetmab with an NSAID and explore what the findings mean for today’s treatment strategies.
Sponsored by Zoetis
Contact us:
Where to find us:
- Cliniciansbrief.com/podcasts
- Facebook.com/clinciansbrief
- Twitter: @cliniciansbrief
- Instagram: @clinicians.brief
The Team:
- Beth Molleson, DVM - Host
- Sarah Pate - Producer & Project Manager, Brief Studio
- Taylor Argo - Podcast Production & Sound Editing
LIBRELA IMPORTANT SAFETY INFORMATION: For use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid selfinjection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be used in breeding, pregnant or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab. The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis. See full Prescribing Information at LibrelaPI.com
353 episodes
Manage episode 519211772 series 2641903
NSAIDs have long been the cornerstone of pharmaceutical pain relief for dogs with OA. But with the arrival of an OA monoclonal antibody therapy, is it time to rethink our approach? In this episode of Clinician’s Brief Partner Podcast, Dr. Beth invites renowned orthopedic expert Dr. John Innes to discuss how he approaches OA management, drawing from >4 years of experience with bedinvetmab in the United Kingdom. They also dive into a head-to-head study comparing bedinvetmab with an NSAID and explore what the findings mean for today’s treatment strategies.
Sponsored by Zoetis
Contact us:
Where to find us:
- Cliniciansbrief.com/podcasts
- Facebook.com/clinciansbrief
- Twitter: @cliniciansbrief
- Instagram: @clinicians.brief
The Team:
- Beth Molleson, DVM - Host
- Sarah Pate - Producer & Project Manager, Brief Studio
- Taylor Argo - Podcast Production & Sound Editing
LIBRELA IMPORTANT SAFETY INFORMATION: For use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid selfinjection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be used in breeding, pregnant or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab. The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis. See full Prescribing Information at LibrelaPI.com
353 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.